Experts discuss the underutilization of biomarker testing in metastatic lung cancer, emphasizing the need for improved ...

If you or a loved one has lung cancer, you may be looking into different treatment options. One new medicine you may hear about is Ensacove (ensartinib). In December 2024, the FDA approved Ensacove as ...

From new imaging and targeted therapies to patient journeys, 2025 highlighted key advances and personal stories in lung ...

In Brazil, the early detection of genetic alterations in lung cancer through liquid biopsies could be a valuable tool for ...

There are many treatment options for lung cancer, but the right one for you will depend on many factors including the type of lung cancer you have. Non-small-cell lung cancer (NSCLC) is the most ...

The FDA approved ensartinib (Ensacove) as a first-line treatment for adults with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC), the agency announced on Wednesday.

A 62-year-old woman with stage IIIA lung cancer faces complex diagnostic and treatment decisions, highlighting the importance ...

Following in the footsteps of several Big Pharma companies, another ALK inhibitor has made its entry into the U.S. The new entrant is ensartinib from Xcovery Holdings, a subsidiary of China’s Betta ...

Matthew Herper covers medical innovation — both its promise and its perils. The biotechnology firm Nuvalent said Monday that its drug for a genetically defined type of lung cancer shrank tumors in ...

About five percent of lung adenocarcinomas, one of the most common forms of lung cancer, are driven by a faulty fusion of two genes, EML4 and ALK. This fusion results in different variants, and until ...